Evaluate Leading Biopharma’s Validated Approaches to Selecting Reproducible, Physiologically Relevant Oncology Models Maximizing Predictability & Efficiency in Therapeutic Development
Join the West Coast's premier pharma and biotech gathering in 2027, the Tumor Models Summit San Francisco, where innovation meets opportunity in tumor modeling.
As the FDA phases out animal testing requirements and NIH redirects funding away from animal-only studies, the oncology landscape is transforming. Exciting modalities like ADCs, bispecifics, T-cell engagers demand smarter, more predictive models. CRISPR and AI are accelerating patient-derived model development at unprecedented speed.
The 2026 meeting united industry leaders with cutting-edge vendors to navigate this pivotal shift. Networking with pioneers shaping the future of optimizing model selection strategy, attendees discovered breakthrough technologies, and positioned their pipeline ahead of the curve. The industry is evolving; the time is now to be part of the conversation.
The Tumor Models Conference offers a valuable snapshot of current research efforts within the in vivo pharmacology research community. It also serves as a collaborative forum where peers can exchange ideas, address shared challenges, and explore potential solutions together.
Jessica Orf, Principal Scientist II, Gilead Sciences
I really enjoy learning what others in the field are working on and having the chance to share what we’re doing at Atomic AI. Last year, I participated in one of the roundtable sessions, which I found especially valuable, the open discussion format encouraged great questions and meaningful exchanges among participants.
Timothy Sproul, Director, Atomic AI
High-quality presentations by experts providing both general context and recent data driving the field forward.
2025 Guest, Co-Founder & Chief Executive Officer, Omios Biologics, 2025 Attendee
Explore the 2026 Event Guide
- Access the full agenda, speaker lineup, and session topics in one comprehensive document
- Evaluate how each case study and expert-led discussion aligns with your current preclinical work and therapeutic candidates
- Share easily with your colleagues and decision makers to demonstrate value and mobilize attendance
- Discover the leading speakers sharing cutting-edge strategies for effective model selection and preclinical development
2026 Speakers
2026 Official Partners
Attending Companies Included:
Explore Related Events
Explore the Agenda
Discover cutting-edge model selection strategies from West Coast biopharma and academic pioneers across models like organoids, xenografts, humanized models, and breakthrough modalities.
Partner With Us
Connect your tumor models and preclinical services with biopharma innovators driving the future of oncology drug development.
Join Cross-Modality Leaders
Network with experts in ADCs, bispecifics, degraders, cell therapy, and T-cell engagers advancing model translatability for faster, smarter preclinical pipelines.